Open access · CC-BY
via OpenAlex
Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty
Samuel Golpanian, Darcy L. DiFede, Aisha Khan, Ivonne Hernandez Schulman, Ana Marie Landin, Bryon A. Tompkins, Alan W. Heldman, Roberto Augusto Miki, Bradley J. Goldstein, Muzammil Mushtaq, Silvina Levis-Dusseau, JOHN J. BYRNES, Maureen H. Lowery, Makoto Natsumeda, Cindy Delgado
The Journals of Gerontology Series A · 2017 · ▲ 106 citations
Abstract
BACKGROUND: Impaired endogenous stem cell repair capacity is hypothesized to be a biologic basis of frailty. Therapies that restore regenerative capacity may therefore be beneficial. This Phase 1 study evaluated the safety and potential efficacy of intravenous, allogeneic, human mesenchymal stem cell (allo-hMSC)-based therapy in patients with aging frailty. METHODS: In this nonrandomized, dose-escalation study, patients received a single intravenous infusion of allo-hMSCs: 20-million (n = 5), 100-million (n = 5), or 200-million cells (n = 5). The primary endpoint was incidence of any treatment-emergent serious adverse events measured at 1 month postinfusion. The secondary endpoints were functional efficacy domains and inflammatory biomarkers, measured at 3 and 6 months, respectively. RESULTS: There were no treatment-emergent serious adverse events at 1-month postinfusion or significant donor-specific immune reactions during the first 6 months. There was one death at 258 days postinfusion in the 200-million group. In all treatment groups, 6-minute walk distance increased at 3 months (p = .02) and 6 months (p = .001) and TNF-α levels decreased at 6 months (p < .0001). Overall, the 100-million dose showed the best improvement in all parameters, with the exception of TNF-α, which showed an improvement in both the 100- and 200-million groups (p = .0001 and p = .0001, respectively). The 100-million cell-dose group also showed significant improvements in the physical component of the SF-36 quality of life assessment at all time points relative to baseline. CONCLUSIONS: Allo-hMSCs are safe and immunologically tolerated in aging frailty patients. Improvements in functional and immunologic status suggest that ongoing clinical development of cell-based therapy is warranted for frailty.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/gerona/glx056
- Canonical
- link ↗
- Fetched
- 2026-11-06 MST
Cite this
APA
Golpanian, S., DiFede, D.L., Khan, A., Schulman, I.H., Landin, A.M., Tompkins, B.A., Heldman, A.W., Miki, R.A., Goldstein, B.J., Mushtaq, M., Levis-Dusseau, S., BYRNES, J.J., Lowery, M.H., Natsumeda, M., Delgado, C., Saltzman, R., Vidro-Casiano, M., Pujol, M.V., Fonseca, M.D., & Oliva, A.A. (2017). Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty. <em>The Journals of Gerontology Series A</em>. https://doi.org/10.1093/gerona/glx056
Vancouver
Golpanian S, DiFede DL, Khan A, Schulman IH, Landin AM, Tompkins BA, et al. Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty. The Journals of Gerontology Series A. 2017. doi:10.1093/gerona/glx056.
BibTeX
@article{samuel2017Alloge,
title = {Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty},
author = {Samuel Golpanian and Darcy L. DiFede and Aisha Khan and Ivonne Hernandez Schulman and Ana Marie Landin and Bryon A. Tompkins and Alan W. Heldman and Roberto Augusto Miki and Bradley J. Goldstein and Muzammil Mushtaq and Silvina Levis-Dusseau and JOHN J. BYRNES and Maureen H. Lowery and Makoto Natsumeda and Cindy Delgado and Russell Saltzman and Mayra Vidro-Casiano and Marietsy V. Pujol and Moisaniel Da Fonseca and Anthony A. Oliva and Geoff Green and Courtney Premer and Audrey Medina and Krystalenia Valasaki and Victoria Florea},
journal = {The Journals of Gerontology Series A},
year = {2017},
doi = {10.1093/gerona/glx056},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Journals of Gerontology Series A 2017
Open access · CC-BY
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Longeveron Inc. 2014
Open access · US-GOV
A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty
The Foundation for Orthopaedics and Regenerative Medicine 2022
Open access · US-GOV
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty
Signal Transduction and Targeted Therapy 2020
Open access · CC-BY
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial
Blood 2011
Citation only
Telomere Shortening and Chromosomal Instability in Chronic Lymphocytic Leukemia
Frontiers in Aging 2023
Open access · CC-BY